Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults
Results from the Phase III EMPEROR-Reduced trial were published in The New England Journal of Medicine
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
cardiology
DRL in collaboration with Amgen in India
DRL to market and distribute Amgen’s Repatha, Kyprolis and BLINCYTO in India upon approval
Dr Reddy’s Laboratories (DRL) has…